BC Innovations | Dec 10, 2015
Distillery Therapeutics

Therapeutics: Homeobox A9 (HOXA9); poly(ADP-ribose) polymerase (PARP); myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX)

Cancer INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting HOXA9 and PARP could help treat MLL-rearranged AML. In primary AML cells from patients and mouse hematopoietic cells transformed with human leukemia-associated...
BC Innovations | Jan 30, 2014
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML) MicroRNA-196b (miR-196b); miR-21 Patient sample, mouse and in vitro studies suggest inhibiting miR-196b and miR-21 could help...
BC Week In Review | Nov 21, 2011
Clinical News

ConfirmMDx for Lung Cancer diagnostic data

Data from sputum samples from 40 NSCLC patients and 52 symptomatic, cancer-free controls showed that using methylation specific PCR to screen for the methylated Ras association domain family 1A (RASSF1A) gene produced 60% sensitivity and...
Items per page:
1 - 3 of 3